KR20240165486A - 아리피프라졸 주사가능한 제제의 투여 방법 - Google Patents
아리피프라졸 주사가능한 제제의 투여 방법 Download PDFInfo
- Publication number
- KR20240165486A KR20240165486A KR1020247038040A KR20247038040A KR20240165486A KR 20240165486 A KR20240165486 A KR 20240165486A KR 1020247038040 A KR1020247038040 A KR 1020247038040A KR 20247038040 A KR20247038040 A KR 20247038040A KR 20240165486 A KR20240165486 A KR 20240165486A
- Authority
- KR
- South Korea
- Prior art keywords
- aripiprazole
- salt
- patient
- injectable formulation
- injectable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 title claims abstract description 283
- 229960004372 aripiprazole Drugs 0.000 title claims abstract description 268
- 238000000034 method Methods 0.000 title claims abstract description 97
- 238000002360 preparation method Methods 0.000 title claims description 24
- 239000007972 injectable composition Substances 0.000 claims abstract description 146
- 201000000980 schizophrenia Diseases 0.000 claims abstract description 50
- 208000028683 bipolar I disease Diseases 0.000 claims abstract description 41
- 150000003839 salts Chemical class 0.000 claims description 108
- 238000007918 intramuscular administration Methods 0.000 claims description 55
- 239000000375 suspending agent Substances 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 37
- 239000002202 Polyethylene glycol Substances 0.000 claims description 31
- 229920001223 polyethylene glycol Polymers 0.000 claims description 31
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 30
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 30
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 30
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 30
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 30
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 30
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 30
- 210000003205 muscle Anatomy 0.000 claims description 29
- 238000002347 injection Methods 0.000 claims description 27
- 239000007924 injection Substances 0.000 claims description 27
- 238000009472 formulation Methods 0.000 claims description 26
- 230000036470 plasma concentration Effects 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 239000011164 primary particle Substances 0.000 claims description 20
- 239000007909 solid dosage form Substances 0.000 claims description 19
- UXQBDXJXIVDBTF-UHFFFAOYSA-N 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1h-quinolin-2-one;hydrate Chemical group O.ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl UXQBDXJXIVDBTF-UHFFFAOYSA-N 0.000 claims description 12
- -1 Abilify Maintena(R) Chemical compound 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 5
- 239000008215 water for injection Substances 0.000 claims description 5
- 230000009974 thixotropic effect Effects 0.000 claims description 4
- 229940105329 carboxymethylcellulose Drugs 0.000 description 25
- 238000011282 treatment Methods 0.000 description 25
- 210000000852 deltoid muscle Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000002612 dispersion medium Substances 0.000 description 5
- 230000002411 adverse Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000013265 extended release Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000007935 oral tablet Substances 0.000 description 4
- 229940071643 prefilled syringe Drugs 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 206010022086 Injection site pain Diseases 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000005414 inactive ingredient Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 208000020925 Bipolar disease Diseases 0.000 description 2
- 208000007220 Cytochrome P-450 CYP2D6 Inhibitors Diseases 0.000 description 2
- 208000009011 Cytochrome P-450 CYP3A Inhibitors Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 2
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000024714 major depressive disease Diseases 0.000 description 2
- 150000004682 monohydrates Chemical group 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 1
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000017911 HTR1A Human genes 0.000 description 1
- 101150015707 HTR1A gene Proteins 0.000 description 1
- 101150104779 HTR2A gene Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920003079 Povidone K 17 Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229940025370 aripiprazole 400 mg Drugs 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 229940127236 atypical antipsychotics Drugs 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- KHLVKKOJDHCJMG-QDBORUFSSA-L indigo carmine Chemical compound [Na+].[Na+].N/1C2=CC=C(S([O-])(=O)=O)C=C2C(=O)C\1=C1/NC2=CC=C(S(=O)(=O)[O-])C=C2C1=O KHLVKKOJDHCJMG-QDBORUFSSA-L 0.000 description 1
- 235000012738 indigotine Nutrition 0.000 description 1
- 239000004179 indigotine Substances 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000011418 maintenance treatment Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000011163 secondary particle Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063003544P | 2020-04-01 | 2020-04-01 | |
| US63/003,544 | 2020-04-01 | ||
| PCT/JP2021/014192 WO2021201238A1 (en) | 2020-04-01 | 2021-04-01 | Methods of administering an aripiprazole injectable preparation |
| KR1020227037401A KR102732030B1 (ko) | 2020-04-01 | 2021-04-01 | 아리피프라졸 주사가능한 제제의 투여 방법 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227037401A Division KR102732030B1 (ko) | 2020-04-01 | 2021-04-01 | 아리피프라졸 주사가능한 제제의 투여 방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240165486A true KR20240165486A (ko) | 2024-11-22 |
Family
ID=75581573
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247038040A Pending KR20240165486A (ko) | 2020-04-01 | 2021-04-01 | 아리피프라졸 주사가능한 제제의 투여 방법 |
| KR1020227037400A Pending KR20220161402A (ko) | 2020-04-01 | 2021-04-01 | 아리피프라졸 치료의 용량 개시 방법 |
| KR1020227037401A Active KR102732030B1 (ko) | 2020-04-01 | 2021-04-01 | 아리피프라졸 주사가능한 제제의 투여 방법 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227037400A Pending KR20220161402A (ko) | 2020-04-01 | 2021-04-01 | 아리피프라졸 치료의 용량 개시 방법 |
| KR1020227037401A Active KR102732030B1 (ko) | 2020-04-01 | 2021-04-01 | 아리피프라졸 주사가능한 제제의 투여 방법 |
Country Status (16)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050032811A1 (en) * | 2003-08-06 | 2005-02-10 | Josiah Brown | Methods for administering aripiprazole |
| US20230129919A1 (en) | 2020-04-01 | 2023-04-27 | Otsuka Pharmaceutical Co., Ltd. | Methods for dose initiation of aripiprazole treatments |
| WO2024194955A1 (en) | 2023-03-17 | 2024-09-26 | Otsuka Pharmaceutical Co., Ltd. | Methods of dispersing aripiprazole injectable preparations |
| CN120957722A (zh) | 2023-04-26 | 2025-11-14 | 大塚制药株式会社 | 用阿立哌唑治疗精神分裂症或i型双相障碍的剂量启动 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7053092B2 (en) | 2001-01-29 | 2006-05-30 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1a receptor subtype agonist |
| AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| US20050032811A1 (en) | 2003-08-06 | 2005-02-10 | Josiah Brown | Methods for administering aripiprazole |
| BRPI0415531B8 (pt) * | 2003-10-23 | 2021-05-25 | Otsuka Pharma Co Ltd | formulação de aripiprazol injetável estéril de liberação controlada e método para a sua preparação |
| KR101892745B1 (ko) | 2007-06-25 | 2018-08-28 | 오쓰까 세이야꾸 가부시키가이샤 | 코어/셀 구조를 가진 미소구 |
| CA2655335C (en) | 2007-12-19 | 2016-09-06 | Janssen Pharmaceutica N.V. | Prolonged-release injectable suspensions of paliperidone palmitate, and dosage forms and delivery systems incorporating same |
| JOP20200109A1 (ar) * | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
| US10525057B2 (en) * | 2013-09-24 | 2020-01-07 | Otsuka Pharmaceutical Co., Ltd. | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
| KR20200010320A (ko) | 2017-05-16 | 2020-01-30 | 보우 리버 엘엘씨 | 치료 방법 |
| AU2019230014B2 (en) * | 2018-03-05 | 2024-11-28 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
| CN108498456B (zh) | 2018-05-16 | 2021-01-01 | 丽珠医药集团股份有限公司 | 一种阿立哌唑缓释微球及其制备方法 |
| CN110327296B (zh) | 2019-08-06 | 2021-10-22 | 深圳市泛谷药业股份有限公司 | 一种阿立哌唑长效注射制剂及其制备方法 |
| US20230129919A1 (en) | 2020-04-01 | 2023-04-27 | Otsuka Pharmaceutical Co., Ltd. | Methods for dose initiation of aripiprazole treatments |
-
2021
- 2021-04-01 US US17/907,583 patent/US20230129919A1/en not_active Abandoned
- 2021-04-01 KR KR1020247038040A patent/KR20240165486A/ko active Pending
- 2021-04-01 JP JP2022559751A patent/JP7584535B2/ja active Active
- 2021-04-01 TW TW110112186A patent/TWI865760B/zh active
- 2021-04-01 CA CA3163321A patent/CA3163321C/en active Active
- 2021-04-01 US US17/594,292 patent/US20220160621A1/en not_active Abandoned
- 2021-04-01 MX MX2022012354A patent/MX2022012354A/es unknown
- 2021-04-01 CA CA3212191A patent/CA3212191A1/en active Pending
- 2021-04-01 JP JP2022559750A patent/JP7733000B2/ja active Active
- 2021-04-01 PL PL21720012.0T patent/PL4125903T3/pl unknown
- 2021-04-01 EP EP21720011.2A patent/EP3941470A1/en active Pending
- 2021-04-01 EP EP21720012.0A patent/EP4125903B1/en active Active
- 2021-04-01 BR BR112022018721A patent/BR112022018721A2/pt unknown
- 2021-04-01 WO PCT/JP2021/014192 patent/WO2021201238A1/en not_active Ceased
- 2021-04-01 BR BR112022018647A patent/BR112022018647A2/pt unknown
- 2021-04-01 HU HUE21720012A patent/HUE069157T2/hu unknown
- 2021-04-01 MX MX2022012353A patent/MX2022012353A/es unknown
- 2021-04-01 AU AU2021248212A patent/AU2021248212A1/en active Pending
- 2021-04-01 TW TW110112185A patent/TWI906279B/zh active
- 2021-04-01 WO PCT/JP2021/014194 patent/WO2021201239A1/en not_active Ceased
- 2021-04-01 CN CN202180025911.8A patent/CN115397420A/zh active Pending
- 2021-04-01 TW TW113142852A patent/TW202523329A/zh unknown
- 2021-04-01 HR HRP20241574TT patent/HRP20241574T1/hr unknown
- 2021-04-01 KR KR1020227037400A patent/KR20220161402A/ko active Pending
- 2021-04-01 AU AU2021245713A patent/AU2021245713A1/en active Pending
- 2021-04-01 CN CN202180026022.3A patent/CN115379842A/zh active Pending
- 2021-04-01 EP EP24205231.4A patent/EP4467194A3/en active Pending
- 2021-04-01 CN CN202411916296.1A patent/CN119792290A/zh active Pending
- 2021-04-01 CA CA3136727A patent/CA3136727A1/en active Pending
- 2021-04-01 KR KR1020227037401A patent/KR102732030B1/ko active Active
- 2021-04-01 TW TW114148822A patent/TW202615022A/zh unknown
- 2021-04-01 ES ES21720012T patent/ES2995466T3/es active Active
-
2022
- 2022-09-26 ZA ZA2022/10633A patent/ZA202210633B/en unknown
-
2023
- 2023-03-15 US US18/184,135 patent/US20230225962A1/en not_active Abandoned
-
2024
- 2024-06-03 US US18/732,392 patent/US20240374506A1/en active Pending
- 2024-11-05 JP JP2024193628A patent/JP7891516B2/ja active Active
- 2024-11-26 US US18/959,760 patent/US20260115131A1/en active Pending
-
2025
- 2025-08-21 JP JP2025137577A patent/JP2025176037A/ja active Pending
- 2025-10-08 US US19/352,541 patent/US12691056B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102732030B1 (ko) | 아리피프라졸 주사가능한 제제의 투여 방법 | |
| JP6231385B2 (ja) | 医薬組成物 | |
| US10092523B2 (en) | Long acting pharmaceutical compositions | |
| KR102794804B1 (ko) | 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법 | |
| JP2017132791A (ja) | 組み合わせ組成物 | |
| US12329740B2 (en) | Rescue treatment of post operative nausea and vomiting | |
| CN110974828B (zh) | 化合物Axitinib在制备治疗脑血管疾病的药物中的应用及其药物组合物 | |
| JP5872551B2 (ja) | パラセタモールを含む医薬組成物およびその製造法 | |
| JP2006083190A (ja) | 手術後の悪心および嘔吐の治療のためのグラニセトロンの使用 | |
| HK40077871A (en) | Methods of administering an aripiprazole injectable preparation | |
| CA3052535C (en) | Rescue treatment of post operative nausea and vomiting | |
| CN107921023A (zh) | 用于治疗偏头痛的包含舒马曲坦的药物组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20241114 Application number text: 1020227037401 Filing date: 20221026 |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20241212 Comment text: Request for Examination of Application |